Orthocell Ltd · ASX:OCC
Orthocell — Shareholder Meeting (November 2014)
19 slides from Orthocell's shareholder meeting presentation, Nov 24, 2014
Slide 1: Advancing Tissue Repair and Regeneration
For personal use only Advancing Tissue Repair and Regeneration AGM Investor Presentation 24-11-2014 ASX: OCC Paul Anderson Managing Director
Slide 2: Disclaimer
Disclaimer For personal use only This presentation prepared by Orthocell Pty Ltd ("Company") does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall ther
Slide 3: Company Information
Company Information For personal use only ASX: OCC Orthocell is a commercial Share price $0.43 stage regenerative medicine Shares on issue 82,500,000 company. Market cap $31,350 million 5,912,500 (exerciseable @ Options outstanding $0.50) Stone Ridge Entities 12.34% • Orthocell’s lead product, Paul
Slide 4: Product Overview
Product Overview For personal use only Orthocell Cell-Based Therapies Celgro™ Scaffold Tendon Cartilage Cell - Based Ortho Gen. Surgical regeneration Regeneration Therapies Applications Applications Ortho-ATI™ Ortho-ACI™ $3,200 injection $6,500 procedure 250 patients treated 300 patients tre
Slide 5: Three complementary platforms
Three complementary platforms For personal use only Ortho-ATI™ CelGro™ Ortho-ACI™ Tendon repair and regeneration Collagen scaffold for repair of Cartilage repair and therapy utilizing the patients’ soft tissue injuries or regeneration therapy utilizing Description own cultured tendon stem cells dege
Slide 6: Large market for tendon repair
Large market for tendon repair For personal use only Shoulder pain & rotator cuff injury 22% in our population Tennis Elbow 3% in our population Achilles tendon rupture 11% in regular runners ACL rupture 1.5-5.5 per 10,000 population
Slide 7: Large market for tendon repair
Large market for tendon repair For personal use only • Tendon injury is very common, particularly in active people: - Over 250,000 rotator cuff injuries need surgery in the US each year - Tennis elbow affects 1%-3% of the population - Over 200,000 Achilles tendon sports injuries in the US each year
Slide 8: Ortho-ATI - tendon regeneration
Ortho-ATI™ - tendon regeneration For personal use only Proprietary method for expanding and cultivating tendon stem cells (Tenocytes) GMP process Re-inject Tendon biopsy to expand and tenocyte cells at from patient cultivate site of tendon patient’s cells injury ATI = autologous tenocyte implantatio
Slide 9: Ortho-ATI - three trials completed
Ortho-ATI™ - three trials completed For personal use only • ATI Tennis Elbow (2012) - 20 patient prospective study - Published (2013) in the prestigious American Journal Sports Medicine - 4.5 year data published showing successful long-term treatment - Ortho-ATI™ disruptive technology and a disease
Slide 10: Tennis elbow trial data
Tennis elbow trial data 4.5 yr. Clinical Results For personal use only
Slide 11: Ortho-ATI Gluteal Tendon - 2yr Clinical Results
Ortho-ATI™ Gluteal Tendon - 2yr Clinical Results - For personal use only 48 Oxford44 p<0.00 Hip 40 Score 36 (0-48) 32 28 24 20 Pre-treatment 3 months 6 months 12 months 24 months Pre- and Post-injection Timeline 10 48 VAS 8 44 Pain SF-36 (0-10) 6 (PCS) 40 36 p<0.001 4 32 28 2 p<0.00 24 0 20 Pre- and
Slide 12: For personal use only
For personal use only • Tennis Elbow ATI can structurally repaired tendon tissue in patients with Severe chronic Resistance Lateral Epicondylitis. Long term data (3-5yrs)demonstrates durability and effectivenss • Gluteal Tendinopathy (Hip) ATI has demonstrated significant clinical improvement at 3 m
Slide 13: Human tendon derived cells generate neo-tendon tissue ex vivo in Bioreactors
A Human tendon derived cells generate neo-tendon tissue ex vivo in Bioreactors For personal use only Human engineered tendon cultured for 7 day with 6% cyclic tensile strain Red: Actin; Blue: Nucleus; Green: Auto fluorescence (collagen & elastin)
Slide 14: Construction of scaffold free engineered tendon
Construction of scaffold free engineered tendon For personal use only Strain (%) 6 1 2 3 4 5 6 Time (s)
Slide 15: CelGro Collagen Scaffold
CelGro™ Collagen Scaffold For personal use only CelGro™ is a collagen derived medical device for orthopaedic and other soft tissue regeneration • CelGro™ is manufactured using a proprietary technology that gives it unique properties: - high mechanical strength - highly pliable - high purity (non-inf
Slide 16: Collagen Scaffold
Collagen Scaffold For personal use only Surgically implanted scaffold repairs soft tissue defects and injuries. Multiple market ready applications: Orthopaedic: biomechanical support and/or cell delivery, Tendon augmentation and repair, Bone repair and regeneration Dental: Guided bone regeneration o
Slide 17: Independent Research Notes
Independent Research Notes For personal use only • Foster Stockbroking (23.09.2014) ‘With two proprietary , mass market regenerative medicine treatments on the cusp of global commercialisation, we believe OCC is well positioned to transition into a significant player in the Biotech sector’ • Smart I
Slide 18: Investment Highlights
Investment Highlights For personal use only 19
Slide 19: Thank you
For personal use only Advancing Tissue Repair and Regeneration Thank you ASX: OCC Paul Anderson Managing Director